Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) EBITDA (2020 - 2025)

Biofrontera has reported EBITDA over the past 6 years, most recently at $4.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 366.3% year-over-year to $4.6 million; the TTM value through Dec 2025 reached -$11.3 million, up 34.08%, while the annual FY2025 figure was -$11.3 million, 34.06% up from the prior year.
  • EBITDA for Q4 2025 was $4.6 million at Biofrontera, up from -$6.3 million in the prior quarter.
  • Over five years, EBITDA peaked at $4.6 million in Q4 2025 and troughed at -$16.1 million in Q3 2021.
  • A 5-year average of -$4.7 million and a median of -$4.8 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 911.17% in 2021 and later skyrocketed 366.3% in 2025.
  • Year by year, EBITDA stood at -$1.9 million in 2021, then plummeted by 193.58% to -$5.6 million in 2022, then soared by 30.75% to -$3.9 million in 2023, then skyrocketed by 55.71% to -$1.7 million in 2024, then skyrocketed by 366.3% to $4.6 million in 2025.
  • Business Quant data shows EBITDA for BFRI at $4.6 million in Q4 2025, -$6.3 million in Q3 2025, and -$5.1 million in Q2 2025.